Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.

Margot NA, Wong P, Kulkarni R, White K, Porter D, Abram ME, Callebaut C, Miller MD.

J Infect Dis. 2017 Mar 15;215(6):920-927. doi: 10.1093/infdis/jix015.

PMID:
28453836
2.

Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>.

Post FA, Yazdanpanah Y, Schembri G, Lazzarin A, Reynes J, Maggiolo F, Yan M, Abram ME, Tran-Muchowski C, Cheng A, Rhee MS.

HIV Clin Trials. 2017 May;18(3):135-140. doi: 10.1080/15284336.2017.1291867. Epub 2017 Mar 17.

PMID:
28303753
3.

Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults.

Raffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E, Henry K, Santana-Bagur J, Stein DK, Bellos N, Scarsella A, Yan M, Abram ME, Cheng A, Rhee MS.

J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):226-231. doi: 10.1097/QAI.0000000000001344.

4.

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.

Abram ME, Ram RR, Margot NA, Barnes TL, White KL, Callebaut C, Miller MD.

PLoS One. 2017 Feb 17;12(2):e0172206. doi: 10.1371/journal.pone.0172206. eCollection 2017.

5.

Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.

Post FA, Tebas P, Clarke A, Cotte L, Short WR, Abram ME, Jiang S, Cheng A, Das M, Fordyce MW.

J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):180-184. doi: 10.1097/QAI.0000000000001186.

6.

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.

Gallant JE, Daar ES, Raffi F, Brinson C, Ruane P, DeJesus E, Johnson M, Clumeck N, Osiyemi O, Ward D, Morales-Ramirez J, Yan M, Abram ME, Plummer A, Cheng AK, Rhee MS.

Lancet HIV. 2016 Apr;3(4):e158-65. doi: 10.1016/S2352-3018(16)00024-2. Epub 2016 Mar 14.

PMID:
27036991
7.

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.

Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, Avihingsanon A, Crofoot G, Benson P, Lichtenstein K, Ramgopal M, Chetchotisakd P, Custodio JM, Abram ME, Wei X, Cheng A, McCallister S, SenGupta D, Fordyce MW; GS-US-292-0112 Study Team.

J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):530-7. doi: 10.1097/QAI.0000000000000908.

8.

Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results.

Gallant JE, Koenig E, Andrade-Villanueva JF, Chetchotisakd P, DeJesus E, Antunes F, Arastéh K, Rizzardini G, Fehr J, Liu HC, Abram ME, Cao H, Szwarcberg J.

J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):338-40. doi: 10.1097/QAI.0000000000000598.

9.

Baseline antiretroviral resistance mutations and treatment-emergent resistance in HIV-1 RNA-suppressed patients switching to EVG/COBI/FTC/TDF or continuing on their PI-, NNRTI-, or RAL-based regimen.

Andreatta K, Kulkarni R, Abram ME, Nguyen T, Cao H, Miller MD, White KL.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):519-26. doi: 10.1097/QAI.0000000000000503.

PMID:
25559592
10.

Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment.

Post FA, Winston J, Andrade-Villanueva JF, Fisher M, Liu Y, Beraud C, Abram ME, Graham H, Rhee MS, Cheng AK, Szwarcberg J; Study 118 Team.

J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):310-3. doi: 10.1097/QAI.0000000000000476.

PMID:
25469527
11.

Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment.

McDonald CK, Martorell C, Ramgopal M, Laplante F, Fisher M, Post FA, Liu Y, Curley J, Abram ME, Custodio J, Graham H, Rhee MS, Szwarcberg J.

HIV Clin Trials. 2014 Nov-Dec;15(6):269-73. doi: 10.1310/hct1506-269.

PMID:
25433666
12.

A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors.

Abram ME, Tsiang M, White KL, Callebaut C, Miller MD.

Antimicrob Agents Chemother. 2015 Feb;59(2):838-48. doi: 10.1128/AAC.04163-14. Epub 2014 Nov 17.

13.

Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.

Kulkarni R, Abram ME, McColl DJ, Barnes T, Fordyce MW, Szwarcberg J, Cheng AK, Miller MD, White KL.

HIV Clin Trials. 2014 Sep-Oct;15(5):218-30. doi: 10.1310/hct1505-218.

PMID:
25350960
14.

Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication.

Abram ME, Ferris AL, Das K, Quinoñes O, Shao W, Tuske S, Alvord WG, Arnold E, Hughes SH.

J Virol. 2014 Jul;88(13):7589-601. doi: 10.1128/JVI.00302-14. Epub 2014 Apr 23.

15.

Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.

Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, Niedziela-Majka A, Barnes TL, Novikov N, Chen X, Svarovskaia ES, McColl DJ, White KL, Miller MD.

Antimicrob Agents Chemother. 2013 Jun;57(6):2654-63. doi: 10.1128/AAC.02568-12. Epub 2013 Mar 25.

16.

Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication.

Abram ME, Ferris AL, Shao W, Alvord WG, Hughes SH.

J Virol. 2010 Oct;84(19):9864-78. doi: 10.1128/JVI.00915-10. Epub 2010 Jul 21.

17.
19.

Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation.

Sluis-Cremer N, Arion D, Abram ME, Parniak MA.

Int J Biochem Cell Biol. 2004 Sep;36(9):1836-47.

PMID:
15183348
20.

Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones.

Arion D, Sluis-Cremer N, Min KL, Abram ME, Fletcher RS, Parniak MA.

J Biol Chem. 2002 Jan 11;277(2):1370-4. Epub 2001 Oct 29.

21.

The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells.

Hasinoff BB, Abram ME, Barnabé N, Khélifa T, Allan WP, Yalowich JC.

Mol Pharmacol. 2001 Mar;59(3):453-61.

PMID:
11179439
22.

The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells.

Hasinoff BB, Abram ME, Chee GL, Huebner E, Byard EH, Barnabé N, Ferrans VJ, Yu ZX, Yalowich JC.

J Pharmacol Exp Ther. 2000 Nov;295(2):474-83.

PMID:
11046078

Supplemental Content

Loading ...
Support Center